
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. reported a substantial year-over-year growth in Cell Processing revenue, which increased by 33% to $25.3 million, contributing to total revenues of $28.1 million for Q3 2025, reflecting a 31% growth on a proforma basis. The company achieved a net income of $0.6 million, or $0.01 per share, surpassing previous loss estimates, alongside projected gross margins in the low-60% range for 2025 and continued improvements in adjusted EBITDA margins. Additionally, BioLife's strategic initiatives, including the establishment of a Center to enhance biopreservation and cell processing best practices, are anticipated to further drive the adoption of its products and services within the cell and gene therapy sector.
Bears say
BioLife Solutions Inc. faces significant risks that contribute to a negative outlook, including potential lower-than-projected growth of its products and services, challenges in securing additional customers, and fluctuations in sales driven by emerging markets and foreign exchange rates. Additionally, the company's FY2025 revenue guidance was adjusted downward by approximately $8 million, resulting in an expected revenue range of $95.0-96.0 million, which reflects a moderate year-over-year growth of 27-29%. This adjustment further emphasizes the reliance on its primary revenue driver, the Cell Processing platform, which is forecasted to generate $93.0-94.0 million but also highlights risks associated with concentrated revenue sources.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares